Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners.
Location: Germany, Bavaria, Martinsried
Employees: 51-200
Total raised: $47.39M
Founded date: 2009
Investors 1
| Date | Name | Website |
| - | OrbiMed | orbimed.co... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 18.06.2024 | - | $5M | - |
| 31.12.2022 | - | $16.09M | - |
| 01.02.2022 | Series B | $26.3M | - |
Mentions in press and media 11
| Date | Title | Description |
| 18.06.2024 | Ethris Raises $5M in Funding | Ethris, a Munich, Germany-based biotechnology company advancing next-generation RNA therapeutics and vaccines, raised $5M in funding. The Bill & Melinda Gates Foundation provided the funding. The company intends to use the funds to rapi... |
| 02.01.2023 | German biotech startup Ethris to raise €15M from Cipla EU to develop mRNA-based therapies | Bayern-based Ethris, a company that claims to be paving a new path from genes to therapeutic proteins using its messenger RNA technology platform, announced on Thursday, December 29, that it will raise €15M from Cipla EU — the wholly-owned ... |
| 31.12.2022 | Germany-based Ethris to receive EUR 15 million investment from Cipla EU | Bayern, Germany-based technical innovator in the emerging field of mRNA therapeutics and LNP delivery, Ethris, entered into a definitive agreement with Cipla EU for an equity investment of EUR 15 million. The company announced the funding o... |
| 29.12.2022 | Cipla EU to Invest EUR 15 Million in Ethris, Initiating a Strategic Collaboration | - |
| 01.02.2022 | Ethris Raises $26.3 Million Series B to Advance Pipeline of mRNA-based Therapeutics for Respiratory Diseases | Ethris GmbH, a leading biotechnology company pioneering transformative messenger RNA (mRNA) therapeutics, announced today that it has raised $26.3 Million (€23.3 Million) in a Series B financing round led by Laureus Capital. The proceeds of... |
| 01.02.2022 | Ethris Raises $26.3 Million Series B to Advance Pipeline of mRNA-based Therapeutics for Respiratory Diseases | - |
| 31.01.2022 | Ethris continues research on mRNA therapeutics with fresh USD 26.3m - including against SARS-CoV-2 | Planegg-based biotechnology company Ethris has raised $26.3 million (€23.3 million) in a Series B funding round led by Laureus Capital. Ethris plans to use the money to further develop its mRNA therapeutics and proprietary platform, and to ... |
| 15.09.2021 | Munich proves its strength against COVID-19 at 22. Pharma Trend - Image and Innovation Award | On September 14, the winners of the "Most Innovative Product" award in the category of leap innovations were announced at the "Pharma Trend - Image & Innovation Award". Formycon convinced ahead of Ethris, with third ... |
| 14.01.2014 | With $20M and 15 preclinical candidates, Moderna launches spinoff for mRNA-based cancer drugs | Moderna’s approach employs messenger RNA, which acts as a blueprint for protein production in cell cytoplasm, to enable the body to make its own healing proteins. Last year, AstraZeneca paid $240 million up front for access to 40 drug candi... |
| - | With $20M and 15 preclinical candidates, Moderna launches spinoff for mRNA-based cancer drugs | With a $110 million financing round and big-time deals with AstraZeneca and Alexion Pharmaceuticals in the bag, biotech company Moderna Therapeutics‘ next big move is to spin its pipeline of cancer drug candidates into a new, separate ventu... |
Show more